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Background-—Human ascending thoracic aortic aneurysms (ATAAs) are life threatening and constitute a leading cause of mortality
in the United States. Previously, we demonstrated that collagens a2(V) and a1(XI) mRNA and protein expression levels are
signiﬁcantly increased in ATAAs.
Methods and Results-—In this report, the authors extended these preliminary studies using high-throughput proteomic analysis to
identify additional biomarkers for use in whole blood real-time RT-PCR analysis to allow for the identiﬁcation of ATAAs before
dissection or rupture. Human ATAA samples were obtained from male and female patients aged 6514 years. Both bicuspid and
tricuspid aortic valve patients were included and compared with nonaneurysmal aortas (mean diameter 2.3 cm). Five biomarkers
were identiﬁed as being suitable for detection and identiﬁcation of ATAAs using qRT-PCR analysis of whole blood. Analysis of 41
samples (19 small, 13 medium-sized, and 9 large ATAAs) demonstrated the overexpression of 3 of these transcript biomarkers
correctly identiﬁed 79.4% of patients with ATAA of ≥4.0 cm (P<0.001, sensitivity 0.79, CI=0.62 to 0.91; speciﬁcity 1.00, 95%
CI=0.42 to 1.00).
Conclusion-—A preliminary transcript biomarker panel for the identiﬁcation of ATAAs using whole blood qRT-PCR analysis in men
and women is presented. (J Am Heart Assoc. 2013;2:e000138 doi: 10.1161/JAHA.113.000138)
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A
scending thoracic aortic aneurysms (ATAAs) are a major
cause of morbidity and mortality worldwide, especially in
those older than 65 years.
1–3 Both men and women are
affected, with a considerably increased risk in men compared
with women.
4,5 While ATAAs can occur as a result of genetic
diseases such as Marfan, Ehlers-Danl€ os and Loeyes-Dietz
syndromes, the most common cause of ATAA is through
cardiovascular malformation of the aortic valve. This malfor-
mation resulting in a bicuspid aortic valve (BAV), has a
heritabilityof89%,andhasbeenshowntoaffect1%to2%ofthe
population, and it is known to be associated with the
development of ATAA .
5 The vast majority of ATAAs, however,
are unrelated to aortic valve malformation or heritable degen-
erative disease and occur in patients with a normal cardiovas-
cular formation, with a normal tricuspid aortic valve (TAV).
The presentation of ATAAs is varied and often silent. Thus,
ATAA detection is often fortuitous, with identiﬁcation occur-
ring during a routine physical examination or during an
unrelated medical evaluation. Once suspected, conﬁrmation
by radiography, magnetic resonance imaging, computed
tomography scanning, or ultrasound is needed to allow for
elective surgery or endovascular repair before dissection or
rupture.
At present, there are no biomarkers available to identify
ATAAs before visible symptoms, dissection, or rupture. The
development of a simple and rapid detection methodology to
identify ATAAs that can be performed at major centers and at
centers lacking sophisticated visual technologies is therefore
needed. In this report, we use proteomic analysis of ATAA
tissue to ﬁrst identify proteins altered in ATAA patients
compared with controls. These proteins allowed for the
identiﬁcation of annotation clusters and canonical pathways
associated with ATAA in tissue biopsies. This discovery phase,
or “sieving approach,” allowed for the identiﬁcation of
putative genetic markers of interest.
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ORIGINAL RESEARCHThis approach has been previously used by Liew and
colleagues, who have demonstrated that whole blood provides
a useful complement for tissue biopsy.
6,7 Their work and that
of others have demonstrated that gene proﬁling in the blood
identiﬁes secreted protein transcripts at the tissue level.
8,9
The mechanism for these alterations is the result of the close
association of blood with the tissue. When tissue is damaged,
the genomic pattern in blood is altered to reﬂect that in the
affected organ. Thus, the blood acts as a bioinformational
scout to determine the disease state in the body.
10 This
approach has been successfully used for the diagnosis of
heart failure,
11 Chagas’ disease cardiomyopathy,
12 can-
cer,
10,13 autoimmune diseases,
14 osteoarthritis, rheumatoid
arthritis, and Crohn’s disease.
15 Using this approach, we have
identiﬁed a preliminary cohort of transcript biomarkers
allowing for the rapid identiﬁcation of ATAA in whole blood
using real-time RT-PCR analysis.
Methods
Study Design
Aortic specimens were collected from male and female
control and ATAA patients. Both TAV and BAV ATAA
specimens were obtained. Protein was isolated from 6 control
and 18 ATAA samples and used for proteomic analysis to
identify possible biomarkers. Proteomic analysis was con-
ﬁrmed by Western blot analysis. Transcripts of identiﬁed
proteins up- or down-regulated in ATAA were evaluated
as possible biomarkers (circulating transcript biomarkers).
Following identiﬁcation of putative transcript biomarkers,
qRT-PCR analysis with whole blood was performed on 6 age-
matched healthy volunteers (3 men [aged 6313 years] and
3 women [aged 6115 years]) and 41 ATAA patients (aged
65.313.9 years) consisting of 13 of the 18 ATAA samples
used for proteomic analysis and 28 ATAA patients. All
samples were unique to this study. Statistical analysis was
performed on each group and on the overall group in
comparison with controls.
Aortic Specimens and Patient Characteristics
Aortic specimens were collected during a 2-year period
(October 2009 to September 2011) from patients with
non-AATAs undergoing heart transplantation and patients
undergoing replacement of ATAA. Six specimens were
obtained from patients (3 men and 3 women, mean age
62.57.8 years) who underwent heart transplantation proce-
dures with normal ascending aortic diameters (mean diameter
2.3 cm) and were used as controls. ATAA samples (n=41;
aged 65.313.9 years; mean diameter 5.30.8 cm, P<0.001
versus controls) were obtained at the time of surgery. The
ATAA patients included 35 men (aged 64.014.2 years) and 6
women (aged 73.010.1 years). Patients had either bicuspid
aortic valves (BAVs) (n=17; aged 55.612.9 years) or tricus-
pid aortic valves (TAVs) (n=24; aged 71.810.8 years) and
were subdivided into 3 groups according to the maximal
diameter of the aneurysm: small, with diameters between 4.0
and 4.9 cm (n=19; 3 woman and 16 men); medium sized,
between 5.0 and 5.5 cm (n=13; 1 woman and 12 men); and
large, with diameters >5.5 cm (n=9; 2 women and 7 men).
All patients with ATAA underwent elective surgery and
required graft replacement of the ascending aorta. Aortic
samples from patients with aneurysms secondary to genetic
syndromes such as Marfan, Ehlers-Danl€ os, and Loeys-Dietz
syndromes or with other cardiovascular diseases, cancer, or
chronic disease were excluded from this study. Aortic
replacement was indicated when the size of the aorta was
5.5 cm for TAV or 5.0 cm for BAV. If valve surgery was
indicated, the standard size for aortic replacement was
decreased dependent on tricuspid valve, younger age, or thin
aortic wall (4 to 4.5 cm). None of the specimens analyzed
were atherosclerotic and none were lined with thrombus.
Control specimens were taken from donors to ensure that
these aortas would have minimal alterations in matrix
composition.
Aortic Specimens
Research protocols were approved by the Institutional Review
Board at Beth Israel Deaconess Medical Center, and informed
consents were obtained under Institutional Review Board No.
2007P-000252. Full-thickness biopsy samples containing all 3
layers of the aorta (tunica adventitia, tunica media, and tunica
intima) were collected from the right-lateral aspect of the
ascending aorta (the greater curvature, roughly in line with the
commissure between the right and noncoronary sinuses) in
the operating room, fresh frozen, and stored at 80°C until
analysis.
Proteomic Analysis
Proteomic analysis was performed on 6 control patients (3
men, 3 women; mean age 62.57.8 years) who underwent
heart transplantation procedures with normal ascending
aortic diameters (mean diameter 2.3 cm). ATAA samples
were obtained from 18 patients and sorted by size. Each
group contained 6 samples consisting of 3 men and 3 women.
Each group consisted of 3 TAV and 3 BAV specimens. Mean
age was 6514 years in controls, 6016 years in patients
with small ATAAs (4.0 to 4.9 cm), 598 years in patients with
medium-sized ATAAs (5.0 to 5.5 cm), and 6016 years in
patients with large ATAAs (<5.5 cm). Total aortic tissue
protein was isolated, and quality and purity were assessed by
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HSDS-PAGE, as previously described.
1 High-throughput proﬁl-
ing of protein samples was performed at the Genomics and
Proteomics Center Core facility of the Beth Israel Deaconess
Medical Center using the 8-plex iTRAQ (AB Sciex, Foster City,
CA) labeling protocol and standard MudPIT methodology
coupled with the 4800 MALDI TOF/TOF Plus instrument.
16
Unsupervised and Quality Control Analysis
of Proteomic Data
Raw data were analyzed by using ProteinPilot v3.0 software
with the Paragon algorithm (AB Sciex). Searches were
performed against the latest available FASTA format fully
annotated SwissProt human protein database (UniProtKB/
Swiss-Prot; release 2010–12 [January 18, 2011 to February 7,
2011] downloaded from the website: http://www.uniprot.
org/downloads). Proteins with conﬁdence score >90% and
with at least 2 peptides of 95% identiﬁcation conﬁdence were
used for quality control and differential expression analysis.
Supervised Analysis
To identify the differentially expressed proteins, the relative
protein expression values were compared between groups
(small ATAAs versus controls, medium-sized ATAAs versus
controls, large ATAAs versus controls). Control samples were
matched for age and sex and were used to identify constitutive
protein expression. Proteins were considered overexpressed
in ATAAs relative to control if the iTRAQ ratio of ATAA to
control was >2.0 and if the corresponding maximum control-
to-control ratio was less than the ATAA-to-control ratio.
Similarly, proteins were considered underexpressed in ATAA
relative to control if the iTRAQ ratio of ATAA to control was
<0.5 and if the corresponding minimum control-to-control
ratio was higher than the ATAA-to-control ratio.
Western Blotting
Western blotting was used to conﬁrm proteomic results.
Protein samples (25 lg) from full-thickness aortic tissue from
the site of the maximal diameter containing all 3 layers were
fractionated on 10% Novex Tris-glycine gels (Invitrogen) and
then electroblotted onto nitrocellulose membranes (Invitro-
gen). Protein equivalency, transfer efﬁciency, membrane
blocking, immunoblotting, detection, and densitometry analy-
sis (Image J analysis software; http://rsbweb.nih.gov/ij/)
were performed as previously described.
1
RNA Isolation
Whole blood was collected into PAXgene Blood RNA Tubes
and stored at 4°C until use. RNA was isolated from whole
blood within 5 days of collection. Total RNA was isolated
using the PAXgene Blood RNA Kit (PreAnalytiX, A Qiagen/BD
Company; http://www.preanalytix.com/).
Real-Time RT-PCR
qRT-PCR analysis was performed on 13 of the ATAA samples
used for proteomic analysis and an additional 28 ATAA
samples (see Aortic Specimens and Patient Characteristics).
qRT-PCR analysis was performed using an Eppendorf Real-
plex
2 Mastercycler and software package (Eppendorf North
America). The iScript One-Step RT-PCR Kit with SYBR Green
solution (Bio-Rad) was used for the qRT-PCRs. In brief, 100 ng
of total RNA and 600 nmol/L of both forward and reverse
primers were added to each reaction. No threshold cycle for
any probe was >32. Control and ATAA samples were run for
each primer set in triplicates. Control reactions without
reverse transcriptase were also performed for each reac-
tion.
16
Oligonucleotide primers (Table 1) were designed using
Primer3 (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_
www.cgi) and were synthesized by Oligos ETC, Inc.
Reaction kinetics were optimized for each primer set. RT
of RNA template occurred at 50°C for 10 minutes with
inactivation at 95°C for 5 minutes. Ampliﬁcation and detec-
tion occurred over 40 cycles (denaturing 95°C; 10 seconds,
annealing 60°C; 10 seconds, extension 72°C; 20 seconds,
with plate read at 78°C). Melting curves were performed
for each reaction at the conclusion of the cycling parame-
ters from 60° to 95°C. Fold changes in gene expression
were calculated using the DDCT (ddCT) method.
17 Fold
change was determined using the formula: fold change=
2
[(CT target geneCT 18s) sample(CT target geneCT 18s) control].
Statistical Analysis
Statistical analysis was performed using SAS (version 6.12)
software package (SAS Institute). The meanSEM for all data
was calculated for all variables. Statistical differences
between groups were evaluated by 1-way ANOVA. One-way
ANOVA was used for comparison of patient’s demographics.
Dunnett’s test was used for comparisons between control and
other groups to adjust for the multiplicity of tests. Fisher’s
exact test was used for comparisons of transcript biomarkers
and ATAA prevalence compared with control. Power analysis
was calculated with G*Power 3.1.5 (www.psycho.uni-dues-
seldorf.de/abteilungen/app/gpower3/download-and-register)
(at test positive rate of control 0.1, test positive rate of ATAA
0.8, a error 0.05, b error 0.05, number needed for control 6,
number needed for ATAA 36). Sensitivity and speciﬁcity of
qRT-PCR test for each gene or for combination of genes were
calculated with 95% CIs. Sensitivity/speciﬁcity results were
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Hmeasured as up-regulated transcript biomarker within dis-
eased patients (sensitivity) and down-regulated transcript
biomarker within control patients (speciﬁcity) compared with
controls.
Results
Proteomic Analysis Sample Groups
Samples for proteomic analysis were obtained from 6 control
patients (3 men and 3 women, mean age 62.57.8 years)
who underwent heart transplantation procedures with normal
ascending aortic diameters (mean diameter 2.3 cm). ATAA
samples were obtained from 18 patients and sorted by size.
Each group contained 6 samples, from 3 men and 3 women.
Each group consisted of 3 TAV and 3 BAV specimens. Mean
age was 6514 years in controls, 6016 years in patients
with small ATAAs (4.0 to 4.9 cm), 598 years in patients with
medium-sized ATAAs (5.0 to 5.5 cm), and 6016 years in
patients with large ATAAs (<5.5 cm).
Proteomic Analysis
A total of 3396 proteins were identiﬁed with valid iTRAQ
labeling, of which 369 were identiﬁed with >95% conﬁdence
(P<0.05). From these, 82 proteins were found to be
commonly expressed in all ATAA size groups and controls.
Principal component analysis (PCA) is shown in Figure 1A.
PCA projects multivariate data objects onto a lower-dimen-
sional space while retaining as much of the original variance
as possible. This is necessary because in analyzing proteomic
data; due to a dimensionality problem, the number of proteins
always considerably exceeds the number of samples. Each
principal component is associated with an eigenvalue, which
corresponds to the amount of variability explained by the
corresponding principal component. An eigenvalue is a
measure of strength of each component.
PCA is used to convert a set of observations of possibly
correlated variables to a set of uncorrelated variables called
principal components. The number of principal components is
less than or equal to the number of original variables. Principal
component 1 has the highest variance possible and therefore
accounts for as much variability in the data as feasible.
Principal component 2 has the second highest variance of the
data.
Principal component analysis indicated there was no
difference in differential protein expression patterns between
BAV versus TAV or male versus female (Figure 1A).
However, comparison of all ATAA size groups (small,
medium sized, and large) versus controls identiﬁed 26 unique
iTRAQ validated proteins as being up- or down-regulated
(Figure 1B). Four of these proteins (calponin-1, plastin-3, and
peptidyl-prolyl cis-trans isomerase) were commonly expressed
and up-regulated in all ATAA size groups (Figure 1B).
Hierarchical cluster analysis showed distinct protein
expression patterns among small, medium-sized, and large
ATAA size groups compared with controls (Figure 1B).
Comparison between small ATAAs versus controls, medium-
sized ATAAs versus controls, and large ATAAs versus controls
identiﬁed 13, 17, and 12 proteins, respectively, that were
differentially expressed (Figure 1A).
Analysis of up- and down-regulated proteins in ATAA size
groups indicated that there were 2 unique proteins altered in
small ATAAs (ﬁlamin-A and G protein–coupled receptor 98), 7
unique proteins altered in medium-sized ATAAs (cysteine-rich
protein [CRP] 1, cysteine- and glycine-rich protein [CSRP] 2,
transgelin-2, peroxiredoxin-1, tropomyosin b chain, protein
disulﬁde-isomerase, and lumican), and 5 unique proteins
Table 1. Oligonucleotide Primers Used for Quantitative Real-Time RT-PCR
mRNA Target Forward Primer Reverse Primer
18s 5′-ATGGCCGTTCTTAGTTGGTG-3′ 5′-CGCTGAGCCAGTCAGTGTAG-3′
FHL1 5′-CCTGGTCTAGGCCATCACAT-3′ 5′-TCTTGCATCCAGCACACTTC-3′
ENOA1 5′-GGAGCTTGGCAGAAGTTCAC-3′ 5′-TGATTCACAAGCCGTAGCTG-3′
CSRP1 5′-AAGTCCTGCTACGGCAAGAA-3′ 5′-CACCAATCTTCTGGGCAAAT-3′
CRP2 5′-CCCACCTGCCAGTGTTATTT-3′ 5′-TTGACAGCACAAGGCTCAAC-3′
PPIA 5′-TGTTTGTGGTTGCCAGTCAT-3′ 5′-TCGAGTTGTCCACAGTCAGC-3′
Col a1(I) 5′-CTCTGACTGGAAGAGTGGAGAGTA-3′ 5′-TTGGTGGTTTTGTATTCAATCACT-3′
Col a1(III) 5′-AGTGACCGACAAAATTCCAGTTAT-3′ 5′-CTTTTACTGGTGAGCACAGTCATT-3′
Col a2(V) 5′-TGAGTTGTGGAGCTGACTCTAATC-3′ 5′-TAACAGAAGCATAGCACCTTTCAG-3′
Col a1(XI) 5′GAAATTGTACCTTGGTGCCACCAAC-3′ 5′-GGATGGATGAGAATGAGCACCATAT-3′
Col a1(I) indicates collagen a1(I); Col a1(III), collagen a1(III); Col a2(V), collagen a2(V); Col a1(XI), collagen a1(XI); CRP2, cysteine-rich protein 2; CSRP1, cysteine- and glycine-rich protein 1;
ENOA1, a-enolase 1; FHL1, four and a half LIM domains protein 1; PIPA, peptidyl-prolyl cis-trans isomerase A; 18s, ribosomal 18s.
DOI: 10.1161/JAHA.113.000138 Journal of the American Heart Association 4
Biomarker Identiﬁcation in ATAA Black et al
O
R
I
G
I
N
A
L
R
E
S
E
A
R
C
Haltered in large ATAAs (vimentin, polymerase 1 and transcript
release factor, peroxiredoxin-2, prolargin, and a2-HS-glyco-
protein) (Table 2). Proteomic results were conﬁrmed by
Western blot analysis (Figure 1C through 1E).
Functional Enrichment Analysis
Functional enrichment analysis revealed 11 functional anno-
tation clusters in small ATAAs, 7 annotation clusters in
medium-sized ATAAs, and 6 annotation clusters in large
ATAAs (P<0.05, enrichment score >2.0) were signiﬁcantly up-
regulated (Table 3).
In small and medium-sized ATAAs (4.0 to 5.5 cm),
functional annotation clusters for cytoskeletal protein bind-
ing, actin binding, muscle organ development, glycolysis
pathway, and glycolysis/gluconeogenesis were signiﬁcantly
up-regulated (Table 3). In the large ATAAs (>5.5 cm),
functional annotation clusters for acute inﬂammatory
Figure 1. A, Principal component analysis. B, Hierarchical cluster analysis of differentially expressed proteins. C, Western blot analysis.
D, Immunoblot analysis. E, Coomassie gel. A, Principal component analysis (PCA) indicated no difference in differential protein expression
patterns between BAV vs TAV or male vs female (identiﬁed with gender icon). B, Differentially expressed proteins compared with control were
identiﬁed by supervised analysis on the basis of P value <0.01 in each group. The differentially expressed proteins are identiﬁed with short
descriptions obtained from the SWISS-PROT database. The log-fold change (LFC) in protein expression is shown with pseudocolor scale (1t o1 )
with red denoting up-regulation and green denoting down-regulation. The columns represent LFC comparisons and the rows represent the
proteins. Dendrograms are found on the left side, experimental groups are found on the top, and protein names are found on the right side of the
ﬁgure. C, Representative 10% Novex Tris-glycine gel. Protein samples (25 lg) from full-thickness aortic tissue from the site of the maximal
diameter containing all 3 layers were fractionated on 10% Novex Tris-glycine gel, Validation of proteomic results via Western blot (WB) analysis.
Results displayed as fold changes compared with controls. 1, Control; 2, small ATAAs; 3, medium-sized ATAAs; 4, large ATAAs. D, Image of
immunoblot, performed using mouse monoclonal four and a half LIM domains protein 1 (FHL1) antibody (1:2000 dilution, Abcam, Inc). 1, Control;
2, small ATAAs; 3, medium-sized ATAAs; 4, large ATAAs. E, Image of Coomassie blue–stained gel. MW, Molecular weight marker. 1, Control; 2,
small ATAAs; 3, medium-sized ATAAs; 4, large ATAAs. ATAA indicates ascending thoracic aortic aneurysm; BAV, bicuspid aortic valve; PC1,
principal component 1; TAV, tricuspid aortic valve.
DOI: 10.1161/JAHA.113.000138 Journal of the American Heart Association 5
Biomarker Identiﬁcation in ATAA Black et al
O
R
I
G
I
N
A
L
R
E
S
E
A
R
C
HTable 2. Protein Expression by ATAA Size
Protein Name t-Statistic P Value Control Mean Group Mean No. of Peptides Control SE GRP2 SE
ATAA 4.0 to 4.9 cm
Glyceraldehyde-3-phosphate dehydrogenase 5.954 0.001 0.807 2.446 6 0.15 0.09
G protein–coupled receptor 98* 5.332 0.001 0.657 1.753 2 0.09 0.04
Plastin-3 5.232 0.001 1.553 4.527 2 0.38 0.39
Transgelin 3.977 0.004 1.547 4.417 13 0.35 0.65
Four and a half LIM domains protein 1 3.959 0.004 1.627 5.113 2 0.46 0.81
Fibronectin 3.231 0.009 0.680 2.163 8 0.26 0.31
Prelamin-A/C 3.003 0.013 1.017 1.752 6 0.13 0.12
Filamin-A* 2.904 0.023 0.467 1.626 31 0.13 0.3
Cysteine-rich protein 2 2.691 0.025 7.833 15.130 2 2.88 1.96
Cysteine- and glycine-rich protein 1 2.607 0.026 1.852 3.795 2 0.59 0.57
Calponin-1 2.581 0.041 2.658 7.530 6 0.68 2.1
a-Enolase 1 2.533 0.030 0.873 1.610 5 0.15 0.17
Peptidyl-prolyl cis-trans isomerase A 2.474 0.044 1.000 1.685 3 0.09 0.21
ATAA 5.0 to 5.5 cm
Plastin-3 4.668 0.001 1.553 4.240 2 0.38 0.44
Calponin-1 4.595 0.001 2.658 7.471 6 0.68 0.79
Cysteine- and glycine-rich protein 1 4.215 0.003 1.852 4.664 2 0.59 0.31
Glyceraldehyde-3-phosphate dehydrogenase 4.154 0.001 0.807 1.788 6 0.15 0.18
Four and a half LIM domains protein 1 4.079 0.002 1.627 5.619 2 0.46 0.86
Transgelin 3.843 0.003 1.547 4.731 13 0.35 0.75
a-Enolase 1 3.509 0.005 0.873 1.604 5 0.15 0.14
Cysteine-rich protein 2 3.42 0.006 7.833 20.816 2 2.88 2.48
Transgelin-2 3.345 0.009 4.030 12.031 5 2.04 1.24
Peroxiredoxin-1* 3.327 0.006 1.020 1.586 3 0.11 0.13
Cysteine-rich protein 1* 2.706 0.019 0.710 1.434 3 0.17 0.21
Cysteine- and glycine-rich protein 2* 2.584 0.024 6.757 13.735 2 1.65 2.14
Tropomyosin b chain* 2.548 0.029 0.940 1.463 22 0.09 0.18
Protein S100-A4 2.283 0.048 0.847 1.166 2 0.12 0.08
Peptidyl-prolyl cis-trans isomerase A 2.259 0.050 1.000 1.536 3 0.09 0.22
Protein disulfide-isomerase* 3.564 0.004 1.242 0.820 2 0.06 0.1
Lumican* 3.718 0.004 0.730 0.276 11 0.1 0.07
ATAA >5.5
Plastin-3 4.429 0.009 1.553 5.285 2 0.38 0.75
Peptidyl-prolyl cis-trans isomerase A 3.265 0.051 0.457 0.020 3 0.09 0.23
Protein S100-A4 3.201 0.013 0.847 1.275 2 0.12 0.07
Prelamin-A/C 2.828 0.024 1.017 1.428 6 0.13 0.08
Calponin-1 2.73 0.032 2.658 5.670 6 0.68 0.87
Fibronectin 2.642 0.041 0.680 1.913 8 0.26 0.39
a-Enolase 1 2.602 0.032 0.873 1.388 5 0.15 0.12
Vimentin* 2.381 0.045 1.950 0.940 23 0.32 0.28
Prolargin* 2.454 0.041 0.792 0.395 6 0.14 0.09
Peroxiredoxin-2* 2.491 0.039 0.822 0.450 4 0.11 0.1
a2-HS-glycoprotein* 2.552 0.051 0.457 0.020 2 0.17 0
Polymerase 1 and transcript release factor* 3.137 0.015 1.508 0.673 2 0.23 0.14
t-Statistic indicates fold change compared with control; ATAA, ascending thoracic aortic aneurysm.
*Unique protein expression in ATAA size group.
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and acute-phase response were signiﬁcantly up-regulated. All
annotation clusters were unique to ATAA size with no
common functional annotation clusters found in ATAAs 4.0
to 5.5 cm compared with ATAAs >5.5 cm. No down-
regulated annotation clusters were identiﬁed in any ATAA
size groups (Table 3).
Pathway Analysis
Pathway analysis of all ATAA size groups showed a signiﬁcant
up-regulation of 11 pathways. In small ATAAs (4.0 to 4.9 cm),
4 pathways were signiﬁcantly up-regulated (Figure 2A), while
in medium-sized ATAAs (5.0 to 5.5 cm), 6 pathways were
signiﬁcantly up-regulated (Figure 2B). In large ATAAs, 6
pathways were signiﬁcantly up-regulated (Figure 2C). One
pathway—phenylalanine, tyrosine, and tryptophan biosynthe-
sis—was commonly up-regulated in all ATAAs. There were 2
pathways common in small and medium-sized ATAAs and 3
pathways common between medium-sized and large ATAAs.
Only 1 pathway was common between small and large ATAAs
(ILK signaling).
Real-Time RT-PCR Analysis
For the identiﬁcation of ATAAs in whole blood, RNA biomar-
kers were chosen as determined from proteomic analysis.
qRT-PCR analysis of whole blood demonstrated that tran-
scripts for a-enolase 1 and peptidyl-prolyl cis-trans isomerase
A were up-regulated in all ATAA size groups compared with
nonaneurysm controls and four and a half LIM domains
protein 1 (FHL1), CSRP1, and CRP2 transcripts were up-
regulated in small and medium-sized ATAA groups compared
with nonaneurysm controls.
qRT-PCR analysis of whole blood demonstrated elevated
expression of transcripts for collagen a1(I), collagen a1(III),
collagen a2(V), collagen a1(XI), and FHL1 based in ATAAs
compared with nonaneurysm controls (Table 4). Our results
show that collagen a1(III), collagen a1(XI), and FHL1 were
down-regulated in all control samples, whereas collagen a1(I)
and collagen a2(V) were uniquely up-regulated in 3 individual
control samples.
Based on these results, we have used collagen a1(I),
collagen a1(III), collagen a2(V), collagen a1(XI), and FHL1 for
biomarker analysis of ATAAs in whole blood samples. Using
these 5 biomarkers for whole blood qRT-PCR analysis, we
observed that 3 of these 5 markers were signiﬁcantly
increased in 15 of 19 ATAA samples of 4.0 to 4.9 cm
(79.0% positive) and in 19 of 21 ATAA samples >5.0 cm
(90.5% positive) (Table 4).
Comparison between TAV versus control and BAV versus
control demonstrated that these 5 biomarkers were signiﬁ-
cantly increased in 21 of 23 TAV (91.3% positive) and 12 of
17 BAV (70.6% positive) ATAA samples >4.0 cm (Table 4).
Five ATAA samples were excluded from analysis due to
insufﬁcient sample volume: 4.2 BAV, 4.5 TAV, 5.0 BAV, 5.3
BAV, and 7.0 TAV. These samples were from 3 women and
2 men.
Analysis of biomarkers showed that identiﬁcation of ATAAs
in whole blood samples was possible having only 3 of 5
biomarkers over-expressed compared with control values
(Table 4). Sensitivity, speciﬁcity, probability, and CIs for ATAA
identiﬁcation using 1 to 3 biomarkers for qRT-PCR in whole
blood showed signiﬁcantly higher rates compared with control
blood with varying sensitivity of 0.53 to 0.97 (Table 5).
Table 3. Protein Functional Annotation Clusters for
Ascending Thoracic Aortic Aneurysms (ATAAs) Based on Size
Annotation Cluster Count P Value
Functional annotation clusters for ATAAs 4.0 to 4.9 cm
Cytoskeletal protein binding 5 0.001
Actin binding 4 0.003
Muscle organ development 3 0.012
Actin cytoskeleton organization 3 0.014
Actin filament–based process 3 0.016
Glycolysis pathway 2 0.023
Cytosol 4 0.029
Glycolysis 2 0.038
Glucose catabolic process 2 0.046
Glycolysis/gluconeogenesis 2 0.046
Cytoskeleton organization 3 0.047
Functional annotation clusters for ATAAs 5.0 to 5.5 cm
Muscle organ development 4 0.001
Actin binding 4 0.006
Cytoskeletal protein binding 4 0.019
Regulation of cell size 3 0.021
Glycolysis pathway 2 0.023
Glycolysis/gluconeogenesis 2 0.023
Regulation of cellular component size 3 0.035
Functional annotation clusters for ATAAs >5.5 cm
Acute inflammatory response 3 0.003
Structural molecule activity 4 0.014
Extracellular matrix 3 0.018
Inflammatory response 3 0.027
Acute-phase response 2 0.032
Cytosol 4 0.042
Count, number of proteins in each functional annotation cluster. P value was determined
by Fisher exact test. A P value ≤0.01 indicates the annotation cluster is speciﬁcally
associated (enriched) in the ATAA size group pathway rather than by random chance.
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We present a preliminary biomarker panel for the identiﬁca-
tion of ATAAs in male and female patients with BAVs or TAVs
in whole blood. We have used both BAVs and TAVs and both
male and female patient samples for biomarker identiﬁcation
as we reasoned that to provide clinical efﬁcacy, both BAV and
TAV needed to be included.
18
Proteomic studies were performed to identify likely
candidate biomarkers to use in whole blood analysis by
Figure 2. Pathway analysis based on size. A, Small aneurysms (4.0 to 4.9 cm); B, medium-sized aneurysms (5.0 to 5.5 cm); C, large aneurysms
(>5.5 cm). Pathway analysis was performed by identifying the over-represented GO categories in differentially expressed proteins: this was done
using the Biological Processes and Molecular Functions Enrichment Analysis available from the Database for Annotation, Visualization and
Integrated Discovery (DAVID). Functional pathways are labeled on the abscissa and the log (P value) is on the ordinate. On the right side is the
ratio of proteins in pathway over total proteins and the yellow line shows the ratio of each pathway. The red line is the threshold at P=0.05. Any
pathway that passes the red line is signiﬁcantly enriched. ILK indicates integrin linked kinase; NRF, nuclear respiratory factor; RA, rheumatoid
arthritis; TR/RXR, thyroid hormone receptor/retinoid X receptor.
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differences in differential protein expression between ATAA
and controls. However, we found no difference in differential
protein expression patterns between BAV versus TAV or male
versus female. These ﬁndings agree with Fedak et al,
19 who
demonstrated no difference in differential genomic expression
patterns between BAV versus TAV, and are in agreement with
current proposed mechanisms leading to aortic rupture.
20–22
In both BAV ATAAs and TAV ATAAs, our studies show that
enriched pathways for actin band, cytoskeletal, and LIM
domain proteins were differentially expressed in small and
medium-size ATAA samples, while the pathways for acute
inﬂammatory response and extracellular matrix proteins were
differentially expressed in large ATAA samples.
From these studies, we identiﬁed 8 proteins found in aortic
tissue samples regardless of sex and aortic valve type: a-
enolase 1, peptidyl-prolyl cis-trans isomerase A, plastin-3,
calponin-1, S100-A4, FHL1, CSRP1, and CRP2. These proteins
have been shown to have important roles in modulating ATAA
development through the modulation of matrix metallopro-
teinases (MMPs).
Peptidyl-prolyl cis-trans isomerase A encodes for cyclophilin
A, which has been shown to and have been associated
with extracellular matrix metalloproteinase activation.
23,24
Calponin 1 is a regulator of vascular smooth muscle tone and
has been shown to be a target of MMP2,
25 whereas S100-A4 is
a calcium signal transducer that has been shown to positively
regulate the secretion of MMPs from endothelial cells and
ﬁbroblasts and to regulate the transcriptional activation of
collagenase3(MMP-13)mRNAfollowedbysubsequentrelease
of MMP protein and the proteolytic degradation of extracellular
matrix.
26–28 a-Enolase is a multifunctional protein and is
involved in the synthesis of pyruvate but also acts as a
plasminogen receptor, where it regulates the activation of
plasmin leading to MMP activation and extracellular matrix
degradation.
20CSRP1 is expressed invascular smooth muscle,
andCRP2isacofactorforsmoothmusclecelldifferentiation.
29
Recent knock-out studies have shown that while CSRP1 and
CRP2 are not essential for normal neointimal formation, they
act antagonistically to modulate the smooth muscle response
to pathophysiological stress.
30 Plastin 3 or ﬁmbrin is an actin
binding protein containing a calcium-binding domain and is
dispersed throughout the lamella. Overall, these proteins and
their effects on MMPs and aneurysm formation agree with
clinical data demonstrating that ascending aortic aneurysms
exhibit increased MMP expression in the affected tissue.
21,22
In initial studies, we tested the genetic sequences for all of
these proteins for preliminary diagnostic efﬁcacy using qRT-
PCR analysis of whole blood. Our analysis showed that only
FHL1, a unique protein that has been shown to play an
important role in vascular smooth muscle cell differentiation,
was useful as a transcript biomarker in whole blood analysis
for ATAA identiﬁcation by qRT-PCR analysis.
31 a-Enolase 1,
CSRP1, CRP2, and peptidyl-prolyl cis-trans isomerase A did
not provide general transcript biomarker identiﬁcation in
whole blood samples. Collagen a1(I), collagen a1(III), collagen
a2(V), and collagen a1(XI) were used for qRT-PCR analysis of
whole blood based on our previous studies.
1
Ourdatademonstratethattheidentiﬁcationofpatientswith
ATAA using whole blood analysis is possible and that, by using
only the collagen transcript biomarker expression, levels we
were able to correctly identify 30 of 41 patients with ATAA. We
also show that in 30 of 41 ATAA patients, at least 4 of the 5
biomarkers are up-regulated compared with controls. We
suggest that to properly identify an aneurysm of ≥4.0 cm, at
least 3 of 5 biomarkers must be elevated >1.5-fold (Tables 4
and 5). Using this criterion, 79.4% of ATAA patients were
correctlyidentiﬁed(P<0.001;sensitivity0.79,speciﬁcity1.00).
Table 4. Continued
Red, qRT-PCR fold change up-regulation of a transcript biomarker compared with control; green, qRT-PCR fold change down-regulation of a transcript biomarker compared with control.
ATAA indicates ascending thoracic aortic aneurysm; BAV, bicuspid aortic valve; Col a1(I), collagen a1(I); Col a1(III), collagen a1(III); Col a2(V), collagen a2(V); Col a1(XI), collagen a1(XI);
FHL1, four and a half LIM domains protein 1; ND, not determined; qRT-PCR, real-time RT-PCE; TAV, tricuspid aortic valve.
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of ≥4.0 cm can be performed rapidly and provides a cost-
effective method for screening before the use of expensive
magnetic resonance imaging, computed tomography scan-
ning, or ultrasound evaluation.
32 The ability to provide for
rapid evaluation of potential ATAA in patients using whole
Table 5. Sensitivity, Speciﬁcity, Probability, and CIs for ATAA Identiﬁcation Using 1 to 3 Biomarkers for qRT-PCR in Whole Blood
Positive ATAA
Patients
% of ATAA
Patients P Value Sensitivity 95% CI Speciﬁcity 95% CI
1 Up-regulated transcript biomarker compared with control
FHL1 30 88.2 <0.0001 0.88 0.73 to 0.97 1.00 0.42 to 1.00
Col a1(XI) 36 87.8 <0.0001 0.88 0.74 to 0.96 1.00 0.42 to 1.00
Col a2(V) 33 80.5 0.03 0.81 0.65 to 0.91 0.67 0.22 to 0.96
Col a1(III) 31 75.6 <0.001 0.76 0.60 to 0.88 1.00 0.42 to 1.00
Col a1(I) 29 70.7 0.02 0.71 0.55 to 0.84 0.83 0.36 to 1.00
ATAA patients identified for any 1 transcript
biomarker being up-regulated compared
with control
33 97.1 <0.01 0.97 0.85 to 1.00 0.50 0.12 to 0.88
2 Up-regulated transcript biomarkers compared with control
Col a2(V)+Col a1(XI) 32 78.0 <0.001 0.78 0.63 to 0.89 1.00 0.42 to 1.00
Col a1(XI)+FHL1 26 76.5 <0.001 0.77 0.59 to 0.89 1.00 0.42 to 1.00
Col a2(V)+FHL1 25 73.5 <0.01 0.74 0.56 to 0.87 1.00 0.42 to 1.00
Col a1(III)+Col a1(XI) 30 73.2 <0.01 0.73 0.57 to 0.86 1.00 0.42 to 1.00
Col a1(III)+Col a2(V) 29 70.7 <0.01 0.71 0.55 to 0.84 1.00 0.42 to 1.00
Col a1(I)+Col a1(XI) 28 68.3 <0.01 0.68 0.52 to 0.82 1.00 0.42 to 1.00
Col a1(III)+FHL1 23 67.6 <0.01 0.68 0.50 to 0.83 1.00 0.42 to 1.00
Col a1(I)+Col a1(III) 26 63.4 <0.01 0.64 0.47 to 0.78 1.00 0.42 to 1.00
Col a1(I)+Col a2(V) 26 63.4 <0.01 0.64 0.47 to 0.78 1.00 0.42 to 1.00
Col a1(I)+FHL1 21 61.8 <0.01 0.62 0.44 to 0.78 1.00 0.42 to 1.00
ATAA patients identified for any 2 transcript
biomarkers being up-regulated compared
with control
30 88.2 <0.0001 0.88 0.73 to 0.97 1.00 0.42 to 1.00
3 Up-regulated transcript biomarkers compared with control
Col a1(III)+Col a2(V)+Col a1(XI) 29 70.7 <0.01 0.71 0.55 to 0.84 1.00 0.42 to 1.00
Col a2(V)+Col a1(XI)+FHL1 24 70.6 <0.01 0.71 0.53 to 0.85 1.00 0.42 to 1.00
Col a1(III)+Col a2(V)+FHL1 22 64.7 <0.01 0.65 0.47 to 0.80 1.00 0.42 to 1.00
Col a1(III)+Col a1(XI)+FHL1 22 64.7 <0.01 0.65 0.47 to 0.80 1.00 0.42 to 1.00
Col a1(I)+Col a2(V)+Col a1(XI) 26 63.4 <0.01 0.63 0.47 to 0.78 1.00 0.42 to 1.00
Col a1(I)+Col a1(III)+Col a1(XI) 25 61.0 <0.01 0.61 0.45 to 0.76 1.00 0.42 to 1.00
Col a1(I)+Col a1(XI)+FHL1 20 58.8 0.02 0.59 0.41 to 0.75 1.00 0.42 to 1.00
Col a1(I)+Col a1(III)+Col a2(V) 24 58.5 <0.01 0.59 0.42 to 0.74 1.00 0.42 to 1.00
Col a1(I)+Col a2(V)+FHL1 19 55.9 0.02 0.56 0.38 to 0.73 1.00 0.42 to 1.00
Col a1(I)+Col a1(III)+FHL1 18 52.9 0.02 0.53 0.35 to 0.70 1.00 0.42 to 1.00
ATAA patients correctly identified for any 3
transcript biomarkers being up-regulated
compared with control
27 79.4 <0.001 0.79 0.62 to 0.91 1.00 0.42 to 1.00
P values were given by Fisher’s exact tests comparing the proportions among variables of each screening test and ATAA prevalence. Seven samples in which FHL1 was not determined due
to sample deﬁciency were not included in the analysis. Note that for speciﬁcity, the percentage of control subjects with up-regulated biomarker values was 0% for all except for Col a2(V)
and Col a1(I). ATAA indicates ascending thoracic aortic aneurysm; Col a1(I), collagen a1(I); Col a1(III), collagen a1(III); Col a2(V), collagen a2(V); Col a1(XI), collagen a1(XI); FHL1, four and a
half LIM domains protein 1; qRT-PCR, real-time RT-PCR.
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clinicians and surgeons and should signiﬁcantly decrease
morbidity and mortality in asymptomatic ATAAs. The use of
whole blood allows for a simple approach that can be used at
major hospital centers and at clinics lacking sophisticated
imaging technology.
32
It must be noted that while the present study provides
initial preliminary results based on sample size, the sample
population does not include ethnic diversity as all subjects
were white and therefore applicability to patients of varied
racial heritage cannot be conﬁrmed. The ages of the patients
are representative of our clinical population and may not
reﬂect those of other areas. It is also important to note that
qRT-PCR did not allow for direct replication of the tissue
ﬁnding. The data presented do, however, provide preliminary
data and evidence that ATAAs can be readily identiﬁed in
whole blood samples using qRT-PCR analysis.
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